FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060250861> ?p ?o ?g. }

• W2060250861 endingPage "1182" @default.
• W2060250861 startingPage "1176" @default.
• W2060250861 abstract "We compared total body irradiation (TBI, 700 cGy)/cyclophosphamide (Cy, 3.6 g/m2)/simustine (250 mg/m2) plus antithymocyte globulin (ATG) (TBI/Cy plus ATG) with cytarabine (8 g/m2)/i.v. busulfan (Bu, 9.6 mg/kg)/Cy (3.6 g/m2)/simustine (250 mg/m2) plus ATG (modified Bu/Cy plus ATG) as preparative therapy in T cell–replete haploidentical hematopoietic stem cell transplantation (haplo-HSCT) for acute leukemia. From August 2009 to August 2013, 38 consecutive patients using TBI/Cy plus ATG regimen for T cell–replete haplo-HSCT (TBI group) at our center were eligible, which contained 28 high-risk and 10 standard-risk patients. A nested case-control study was designed. Seventy-seven patients using modified Bu/Cy plus ATG regimen (Bu group) were randomly selected in a 1 to 3:1 ratio matching for age, disease and status, year of HSCT (±2 years), and length of follow-up. Only 1 graft failure occurred in the TBI group. The incidence and time of neutrophil and platelet engraftment were comparable between the 2 groups. Severe grades III/IV graft-versus-host disease was observed in 13.4% of Bu group and only 2.6% of TBI group (P = .083). More toxicity of the liver (37.7% versus 10.5%; P = .002) and more hemorrhagic cystitis occurred in the Bu group (49.3% versus 23.7%, P = .008). Diarrhea was more common in the TBI group (44.7% versus 22.1%; P = .031). No significant differences were found in the 2-year incidences of relapse (26.5% for TBI group versus 32.3% for Bu group, P = .742), 1-year transplant-related mortality (12.6% versus 16.2%, P = .862), 2-year overall survival (60.2% versus 57.0%, P = .937), and 2-year incidence of disease-free survival (57.9% versus 56.6%, P = .845) between the 2 groups. We conclude that the TBI/Cy plus ATG regimen seems to be feasible in T cell–replete haplo-HSCT, which promotes stable engraftment and a lower incidence of liver toxicity and hemorrhagic cystitis. However, longer follow-up is necessary to determine the late relapse rate and late toxicity." @default.
• W2060250861 created "2016-06-24" @default.
• W2060250861 creator A5001508669 @default.
• W2060250861 creator A5021880262 @default.
• W2060250861 creator A5038357890 @default.
• W2060250861 creator A5046424825 @default.
• W2060250861 creator A5051439492 @default.
• W2060250861 creator A5055494772 @default.
• W2060250861 creator A5065894155 @default.
• W2060250861 creator A5072208411 @default.
• W2060250861 creator A5078632164 @default.
• W2060250861 creator A5079594267 @default.
• W2060250861 creator A5084854649 @default.
• W2060250861 creator A5087610827 @default.
• W2060250861 date "2014-08-01" @default.
• W2060250861 modified "2023-10-16" @default.
• W2060250861 title "Total Body Irradiation and Cyclophosphamide Plus Antithymocyte Globulin Regimen Is Well Tolerated and Promotes Stable Engraftment as a Preparative Regimen before T Cell–Replete Haploidentical Transplantation for Acute Leukemia" @default.
• W2060250861 cites W1795844187 @default.
• W2060250861 cites W1959073718 @default.
• W2060250861 cites W1982247089 @default.
• W2060250861 cites W1994916640 @default.
• W2060250861 cites W1997998157 @default.
• W2060250861 cites W2015730284 @default.
• W2060250861 cites W2021767322 @default.
• W2060250861 cites W2026597916 @default.
• W2060250861 cites W2040886821 @default.
• W2060250861 cites W2061660136 @default.
• W2060250861 cites W2061878111 @default.
• W2060250861 cites W2075354097 @default.
• W2060250861 cites W2078641152 @default.
• W2060250861 cites W2079110478 @default.
• W2060250861 cites W2080130915 @default.
• W2060250861 cites W2083611552 @default.
• W2060250861 cites W2085530853 @default.
• W2060250861 cites W2094729406 @default.
• W2060250861 cites W2105900310 @default.
• W2060250861 cites W2111951140 @default.
• W2060250861 cites W2119411875 @default.
• W2060250861 cites W2130040182 @default.
• W2060250861 cites W2141696179 @default.
• W2060250861 cites W2147068163 @default.
• W2060250861 cites W2148388235 @default.
• W2060250861 cites W2148549851 @default.
• W2060250861 cites W2167805334 @default.
• W2060250861 cites W2317548431 @default.
• W2060250861 cites W2618073389 @default.
• W2060250861 doi "https://doi.org/10.1016/j.bbmt.2014.04.012" @default.
• W2060250861 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24747336" @default.
• W2060250861 hasPublicationYear "2014" @default.
• W2060250861 type Work @default.
• W2060250861 sameAs 2060250861 @default.
• W2060250861 citedByCount "17" @default.
• W2060250861 countsByYear W20602508612015 @default.
• W2060250861 countsByYear W20602508612016 @default.
• W2060250861 countsByYear W20602508612017 @default.
• W2060250861 countsByYear W20602508612018 @default.
• W2060250861 countsByYear W20602508612019 @default.
• W2060250861 countsByYear W20602508612020 @default.
• W2060250861 countsByYear W20602508612021 @default.
• W2060250861 countsByYear W20602508612022 @default.
• W2060250861 crossrefType "journal-article" @default.
• W2060250861 hasAuthorship W2060250861A5001508669 @default.
• W2060250861 hasAuthorship W2060250861A5021880262 @default.
• W2060250861 hasAuthorship W2060250861A5038357890 @default.
• W2060250861 hasAuthorship W2060250861A5046424825 @default.
• W2060250861 hasAuthorship W2060250861A5051439492 @default.
• W2060250861 hasAuthorship W2060250861A5055494772 @default.
• W2060250861 hasAuthorship W2060250861A5065894155 @default.
• W2060250861 hasAuthorship W2060250861A5072208411 @default.
• W2060250861 hasAuthorship W2060250861A5078632164 @default.
• W2060250861 hasAuthorship W2060250861A5079594267 @default.
• W2060250861 hasAuthorship W2060250861A5084854649 @default.
• W2060250861 hasAuthorship W2060250861A5087610827 @default.
• W2060250861 hasBestOaLocation W20602508611 @default.
• W2060250861 hasConcept C126322002 @default.
• W2060250861 hasConcept C141071460 @default.
• W2060250861 hasConcept C2776694085 @default.
• W2060250861 hasConcept C2776755627 @default.
• W2060250861 hasConcept C2776863199 @default.
• W2060250861 hasConcept C2777408962 @default.
• W2060250861 hasConcept C2777600175 @default.
• W2060250861 hasConcept C2778041864 @default.
• W2060250861 hasConcept C2778461978 @default.
• W2060250861 hasConcept C2778880498 @default.
• W2060250861 hasConcept C2779972918 @default.
• W2060250861 hasConcept C2780611847 @default.
• W2060250861 hasConcept C2781413609 @default.
• W2060250861 hasConcept C2911091166 @default.
• W2060250861 hasConcept C71924100 @default.
• W2060250861 hasConcept C88879693 @default.
• W2060250861 hasConcept C90924648 @default.
• W2060250861 hasConceptScore W2060250861C126322002 @default.
• W2060250861 hasConceptScore W2060250861C141071460 @default.
• W2060250861 hasConceptScore W2060250861C2776694085 @default.
• W2060250861 hasConceptScore W2060250861C2776755627 @default.
• W2060250861 hasConceptScore W2060250861C2776863199 @default.
• W2060250861 hasConceptScore W2060250861C2777408962 @default.
• W2060250861 hasConceptScore W2060250861C2777600175 @default.

• next